Bank of New York Mellon
AKTS

Bank of New York Mellon’s Aktis Oncology AKTS Stock Holding History

Bank of New York Mellon’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Buy
49,250
+6,349
+15% +$130K ﹤0.01% 3088
2026
Q1 		$767K Buy
+42,901
New +$833K ﹤0.01% 3372

Other funds holding AKTS

BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
GLA
Great Lakes Advisors Chicago, Illinois $13.1B AUM 34.09% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Bank of New York Mellon's AKTS Position: Q2 2026 in Review

Bank of New York Mellon increased its Aktis Oncology (AKTS) stake by 15% in Q2 2026, buying an estimated $130K and bringing the position to 49,250 shares worth $1.59M. The position accounts for ﹤0.01% of the portfolio, ranked #3088.

Bank of New York Mellon first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

  • Bank of New York Mellon held 49,250 shares of Aktis Oncology worth $1.59M as of Q2 2026.
  • Bank of New York Mellon bought 6,349 Aktis Oncology shares in Q2 2026, an estimated $130K.
  • Aktis Oncology made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3088 holding.
  • Bank of New York Mellon first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.